Treats Parkinson's disease. ANDA 202164, held by Macleods Pharmaceuticals. Pramipexole Dihydrochloride.
As of Nov 21, 2026, ANDA 202164 (Pramipexole Dihydrochloride), held by Macleods Pharmaceuticals, was first approved by FDA on Sep 20, 2012, with 8 approved supplements and 0 published complete response letters.
Pramipexole dihydrochloride tablets are a non-ergot dopamine agonist indicated for the treatment of: · Parkinson’s disease (PD)
| Date | Submission | Status | Documents |
|---|---|---|---|
| Sep 20, 2012 | Original application | Approved | None posted |
| Pramipexole Dihydrochloride0.125MG · tablet;oral | Pramipexole Dihydrochloride | Discontinued |
| Pramipexole Dihydrochloride0.25MG · tablet;oral | Pramipexole Dihydrochloride | Discontinued |
| Pramipexole Dihydrochloride0.5MG · tablet;oral | Pramipexole Dihydrochloride | Discontinued |
| Pramipexole Dihydrochloride1MG · tablet;oral | Pramipexole Dihydrochloride | Discontinued |
| Pramipexole Dihydrochloride1.5MG · tablet;oral | Pramipexole Dihydrochloride | Discontinued |
| Jun 7, 2023 | Supplement 22Labeling · Standard review | Approved | None posted |
| Nov 10, 2020 | Supplement 19Labeling · Standard review | Approved | None posted |
| Nov 21, 2019 | Supplement 10Labeling · Standard review | Approved | None posted |
| Nov 21, 2019 | Supplement 15Labeling · Standard review | Approved | None posted |
| May 11, 2016 | Supplement 7Labeling · Standard review | Approved | None posted |
| Dec 2, 2015 | Supplement 4Labeling · Standard review | Approved | None posted |
| Dec 2, 2015 | Supplement 6Labeling · Standard review | Approved | None posted |
| Jul 31, 2013 | Supplement 2Labeling · Standard review | Approved | None posted |
| Sep 20, 2012 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters